Bizarre Patents
An electrified table cloth for preventing crawling insects from gaining access to the consumer's food or drink.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7785621 | Oral compositions of fenretinide having increased bioavailability and methods of using the same The present invention provides an edible composition for oral delivery of an active agent such as a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweete... | 08/31/2010 |
| 7780978 | Oral pharmaceutical compositions and methods of using the same The present invention provides an edible composition for oral delivery of an active agent such as paclitaxel or a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) opt... | 08/24/2010 |
| 7593763 | Non-invasive in vivo measurement of macular carotenoids A non-invasive in vivo method for assessing macular carotenoids includes performing Optical Coherence Tomography (OCT) on a retina of a subject. A spatial representation of carotenoid levels in the macula based on data from the OCT of the retina can be generated. | 09/22/2009 |
| 7553630 | Methods for detecting metalloproteinase inhibitors A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed. ... | 06/30/2009 |
| 7537757 | Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant EMAP II A method of facilitating vascular growth in cardiac muscle of a subject in need of such treatment comprises inhibiting EMAP II activity in said subject by an amount effective to stimulate vascular growth in said cardiac muscle. The inhibiting step may be carried out... | 05/26/2009 |
| 7476692 | Pharmaceutical compositions of safingol and methods of using the same The present invention provides stable aqueous solutions consisting essentially of: (a) a sphingolipid; (b) lactic acid; and (c) optionally a stabilizing agent; wherein the solution has a molar ratio of lactic acid to sphingolipid of 1:1 to 10:1. The present inventio... | 01/13/2009 |
| 7398119 | Assessing blood brain barrier dynamics or identifying or measuring selected substances, including ethanol or toxins, in a subject by analyzing Raman spectrum signals A non-invasive method for analyzing the blood-brain barrier includes obtaining a Raman spectrum of a selected portion of the eye and monitoring the Raman spectrum to ascertain a change to the dynamics of the blood brain barrier. Also, non-invasive methods for... | 07/08/2008 |
| 7264803 | Methods and pharmaceutical formulations for the treatment of pulmonary hypertension A method of treating pulmonary hypertension in a subject in need of such treatment comprises inhibiting EMAP II activity in the subject by an amount effective to treat the pulmonary hypertension in the subject (e.g., in the lungs and more particularly in the pulmona... | 09/04/2007 |
| 7169819 | Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated ca... | 01/30/2007 |
| 6991788 | Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence Described herein are methods for producing recombinant forms of asparaginase derived from Wolinella succinogenes. In addition, methods for covalent modification of proteins, including asparaginases, by acylation are also provided. Certain embodiments provide ... | 01/31/2006 |
| 6984379 | Gene therapy by administration of genetically engineered CD34 cells obtained from cord blood A method of providing a therapeutic effect in a human patient which comprises administering to the patient CD34+ cells obtained from cord blood. The CD34+ cells have been engineered with at least one nucleic acid sequence encoding a therapeutic agent. Such CD34+ cel... | 01/10/2006 |
| 6961599 | Identifying or measuring selected substances or toxins in a subject using resonant raman signals Methods and systems of the present invention identify the presence of and/or the concentration of a selected analyte in a subject by: (a) illuminating a selected region of the eye of a subject with an optical excitation beam, wherein the excitation beam wavelength i... | 11/01/2005 |
| 6905702 | Methods for regulating blood glucose and appetite suppression in type 2 diabetics Methods are disclosed for treating a patient with Type 2 diabetes to decrease hypoglycemic episodes and/or to diminish fluctuations in blood glucose outside of the normal range, comprising administering to said patient, in a therapeutically-effective amount, a food ... | 06/14/2005 |
| 6875749 | Methods of facilitating vascular growth A method of facilitating vascular growth in a subject in need of such treatment comprises inhibiting EMAP II activity in the subject by an amount effective to stimulate vascular growth in the subject (e.g., in the lungs or heart of the subject). Pharmaceutical formu... | 04/05/2005 |
| 6759196 | Method of detecting mitochondrial dysfunction A method of screening a subject for mitochondrial dysfunction comprises detecting the presence or absence of single nucleotide changes in a hypervariable region of the mitochondrial DNA of said subject, the presence of such changes indicating that said subject is af... | 07/06/2004 |
| 6424850 | Non-invasive glucose monitor A non-invasive method for determining blood level of an analyte of interst, such as glucose, comprises: generating an excitation laser beam (e.g., at a wavelength of 700 to 900 nanometers); focusing the excitation laser beam into the anterior chamber of a... | 07/23/2002 |
